Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2017

17.11.2016 | Letter to the Editor

First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer

verfasst von: Kadri Altundag

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Cazzaniga ME, Cortesi L, Ferzi A et al (2016) Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat 160:501–509CrossRefPubMedPubMedCentral Cazzaniga ME, Cortesi L, Ferzi A et al (2016) Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat 160:501–509CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Cinieri S, Chan A, Altundag K et al. Final results of the randomised phase II NorCap-CA223. Trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative MBC. Clin Breast Cancer. doi:10.1016/j.clbc.2016.06.014 Cinieri S, Chan A, Altundag K et al. Final results of the randomised phase II NorCap-CA223. Trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative MBC. Clin Breast Cancer. doi:10.​1016/​j.​clbc.​2016.​06.​014
Metadaten
Titel
First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer
verfasst von
Kadri Altundag
Publikationsdatum
17.11.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4055-x

Weitere Artikel der Ausgabe 2/2017

Breast Cancer Research and Treatment 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.